Literature DB >> 6626444

Sulphaphenazole and drug oxidation in man.

D B Back, B K Park, J F Tjia, S N Newby.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6626444      PMCID： PMC1428019          DOI： 10.1111/j.1365-2125.1983.tb02199.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  7 in total

1.  SULPHAPHENAZOLE-INDUCED HYPOGLYCAEMIC ATTACKS IN TOLBUTAMIDE-TREATED DIABETICS.

Authors:  L K CHRISTENSEN; J M HANSEN; M KRISTENSEN
Journal:  Lancet       Date:  1963-12-21       Impact factor: 79.321

2.  Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man [proceedings].

Authors:  J R Idle; T P Sloan; R L Smith; L A Wakile
Journal:  Br J Pharmacol       Date:  1979-07       Impact factor: 8.739

3.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

4.  A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine.

Authors:  B K Park
Journal:  J Steroid Biochem       Date:  1978-10       Impact factor: 4.292

5.  Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.

Authors:  S M Pond; D J Birkett; D N Wade
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

6.  Pharmacogenetics of tolbutamide metabolism in humans.

Authors:  J Scott; P L Poffenbarger
Journal:  Diabetes       Date:  1979-01       Impact factor: 9.461

7.  Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.

Authors:  M Danhof; E de Groot-van der Vis; D D Breimer
Journal:  Pharmacology       Date:  1979       Impact factor: 2.547
  7 in total
  6 in total

1.  Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.

Authors:  C J Doecke; M E Veronese; S M Pond; J O Miners; D J Birkett; L N Sansom; M E McManus
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

2.  Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors.

Authors:  H S Purba; D J Back; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

3.  2-Hydroxylation of ethinyloestradiol in relation to the oxidation of sparteine and antipyrine.

Authors:  D J Back; J L Maggs; H S Purba; S Newby; B K Park
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

4.  Effects of cimetidine on carbamazepine auto- and hetero-induction in man.

Authors:  G J Macphee; G G Thompson; G Scobie; E Agnew; B K Park; T Murray; K E McColl; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

5.  In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines.

Authors:  D J Back; J F Tjia; J Karbwang; J Colbert
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

6.  Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide.

Authors:  D J Back; J Tjia; H Mönig; E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.